Know Cancer

forgot password

A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Phase 2/Phase 3
18 Years
Open (Enrolling)
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Cancer

Thank you

Trial Information

A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Anthracycline/taxane based combination chemotherapy of at least 18 weeks represents the
standard of care in the neoadjuvant setting. In HER2-positive disease trastuzumab is given
simultaneously to chemotherapy. Recent data from the Neo-Altto and Neosphere trials suggest
that a dual blockage of the HER2 receptor with e.g. trastuzumab and lapatinib reach
significantly higher pCR rates than trastuzumab alone and should therefore represent the
treatment back-bone of new neoadjuvant trials. A preplanned subgroup analysis of the
GeparQuinto study demonstrated that in TNBC the addition of bevacizumab resulted in a
significant increase of pCR rates (HR 1.4).

Having a better cardiac tolerability profile compared to conventional anthracyclines, the
non-pegylated liposomal encapsulated doxorubicin (NPLD) Myocet® might provide the
possibility to combine taxane, anthracycline, platinum salt as well with targeted agents as
double HER2 blockage or bevacizumab.

Inclusion Criteria:

- 1.Written informed consent for all study procedures according to local regulatory
requirements prior to beginning specific protocol procedures.

- 2.Complete baseline documentation must be submitted via Medcodes® and approved by GBG
Forschungs GmbH.

- 3.Unilateral or bilateral primary carcinoma of the breast, confirmed histologically
by core biopsy. Fine-needle aspiration is not sufficient. Incisional biopsy is not
allowed. In case of bilateral cancer, the investigator has to decide prospectively
which side will be evaluated for the primary endpoint.

- 4.Tumor lesion in the breast with a palpable size of ≥ 2 cm or a sonographical size
of ≥ 1 cm in maximum diameter. The lesion has to be measurable in two dimensions,
preferably by sonography. In case of inflammatory disease, the extent of inflammation
can be used as measurable lesion.

- 5.Patients should be in the following stages of disease: cT2 - cT4a-d or cT1c and cN+
or pNSLN+

- 6.In patients with multifocal or multicentric breast cancer, the largest lesion
should be measured.

- 7.Centrally confirmed ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER/PR
positive is defined as >1% stained cells and HER2-positive is defined as HercepTest
IHC 3+ or FISH ratio ≥ 2.2. Formalin-fixed, paraffin-embedded (FFPE) breast tissue
from core biopsy has therefore to be sent to the Dept. of Pathology at the Charité,
Berlin prior to randomization.

- 8.Age ≥ 18 years.

- 9.Karnofsky Performance status index ≥ 80%.

- 10.Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or
shortening fraction) within 3 months prior to randomization. LVEF must be above 55%.

- 11.Laboratory requirements: Hematology

- Absolute neutrophil count (ANC) ≥ 2.0 x 109 / L and

- Platelets ≥ 100 x 109 / L and

- Hemoglobin ≥ 10 g/dL (≥ 6.2 mmol/L) Hepatic function

- Total bilirubin < 1.5x UNL and

- ASAT (SGOT) and ALAT (SGPT) ≤ 1.5x UNL and

- Alkaline phosphatase ≤ 2.5x UNL. Renal function

- Creatinine ≤ 175 µmol/L (2 mg/dL) < 1.5x UNL

- Proteinuria: Urine dipstick for proteinuria < 2+. Patients discovered to have ≥ 2+
proteinuria on dipstick urinalysis should undergo a 24-hour urine collection and must
demonstrate ≤ 1 g of protein in 24 hours. If creatinine is between 140 - 175 umol/L
(1.6-2.0 mg/dL), the creatinine clearance (calculated or measured) should be ≥ 45

- 12.Negative pregnancy test (urine or serum) within 14 days prior to randomization for
all women of childbearing potential.

- 13.Complete staging work-up within 3 months prior to randomization. All patients must
have bilateral mammography, breast ultrasound (≤ 21 days), breast MRI (optional),
chest X-ray (PA and lateral), abdominal ultrasound or CT scan or MRI, and bone scan
done. In case of positive bone scan, bone X-ray (or CT or MRI) is mandatory. Other
tests may be performed as clinically indicated.

- 14.Patients must be available and compliant for central diagnostics, treatment and

Exclusion Criteria:

1. Prior chemotherapy for any malignancy.

2. Prior radiation therapy for breast cancer.

3. Pregnant or lactating patients. Patients of childbearing potential must implement
adequate non-hormonal contraceptive measures (barrier methods, intrauterine
contraceptive devices, sterilization) during study treatment.

4. Inadequate general condition (not fit for anthracycline-taxane-targeted agents-based

5. Previous malignant disease being disease-free for less than 5 years (except CIS of
the cervix and non-melanomatous skin cancer).

6. Known or suspected congestive heart failure (>NYHA I) and / or coronary heart
disease, angina pectoris requiring antianginal medication, previous history of
myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or
poorly controlled arterial hypertension (i.e. BP >160 / 90 mm Hg under treatment with
two antihypertensive drugs), rhythm abnormalities requiring permanent treatment,
clinically significant valvular heart disease.

7. Previous thromboembolic event (except when thrombophily screening is negative).

8. Known hemorrhagic diathesis or coagulopathy with increased bleeding risk.

9. History of significant neurological or psychiatric disorders including psychotic
disorders, dementia or seizures that would prohibit the understanding and giving of
informed consent

10. Pre-existing motor or sensory neuropathy of a severity ≥ grade 2 by NCI-CTC criteria
v 4.0.

11. Currently active infection.

12. Active peptic ulcer.

13. Incomplete wound healing or unhealed bone fracture.

14. Disease significantly affecting gastrointestinal function, e.g. malabsorption
syndrome, resection of the stomach or small bowel, ulcerative colitis.

15. History of abdominal fistula or any grade 4 non-gastrointestinal fistula,
gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment.

16. Severe pulmonary condition / illness.

17. Major surgery within the last 28 days or anticipation of the need for major surgery
during study treatment with bevacizumab. Minor surgeries including insertion of an
indwelling catheter or sentinel lymph node biopsy within 24 h prior to chemotherapy.

18. Definite contraindications for the use of corticosteroids except inhalative

19. Known hypersensitivity reaction to one of the compounds or incorporated substances
used in this protocol;

20. Concurrent treatment with:

- chronic corticosteroids unless initiated > 6 months prior to study entry and at
low dose (≤ 10 mg methylprednisolone or equivalent).

- sex hormones. Prior treatment must be stopped before study entry.

- virostatic agents like sorivudine or analogs like brivudine, concurrent
treatment with aminoglycosides.

- anticoagulants: heparin, warfarin as well as acetylic acid (e.g. Aspirin®) at a
dose of > 325 mg/day or clopidogrel at a dose of > 75 mg/day.

- other experimental drugs or any other anti-cancer therapy.

- drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A,
e.g. Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itraconazole,
Ritonavir, Telithromycin, Erythromycin, Verapamil, Diltiazem within the last 5
days or the expected need for these treatments during study participation.

21. Participation in another clinical trial with any investigational, not marketed drug
within 30 days prior to study entry.

22. Male patients.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Pathological complete response of breast and lymph nodes (ypT0 ypN0; primary endpoint)

Outcome Description:

Pathological response will be assessed considering all removed breast and lymphatic tissues from all surgeries. Surgery takes place shortly after the 18 weeks (six 3-week cycles) chemotherapy treatment. No microscopic evidence of residual viable tumor cells in all resected specimens of the breast and axilla meets the primary endpoint.

Outcome Time Frame:

24 weeks (time window -3 weeks)

Safety Issue:


Principal Investigator

Gunter von Minckwitz, MD, Prof

Investigator Role:

Principal Investigator

Investigator Affiliation:

ASCO, AACR, ESMO, DKG, DGGG, AGO, DGS, BIG, BCIRG, St. Gallen Consensus Panel


Germany: Federal Institute for Drugs and Medical Devices

Study ID:

GBG 66



Start Date:

August 2011

Completion Date:

July 2013

Related Keywords:

  • Tubular Breast Cancer Stage II
  • Mucinous Breast Cancer Stage II
  • Breast Cancer Female NOS
  • Invasive Ductal Breast Cancer
  • Tubular Breast Cancer Stage III
  • HER-2 Positive Breast Cancer
  • Inflammatory Breast Cancer Stage IV
  • Inflammatory Breast Cancer
  • GeparSixto
  • GBG 66
  • GBG
  • German Breast Group
  • neo-adjuvant
  • GBG Forschungs GmbH
  • Tubular breast cancer stage II - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
  • Mucinous breast cancer stage II
  • Invasive ductal breast cancer
  • Tubular breast cancer stage III
  • HER-2 positive breast cancer
  • Inflammatory breast cancer stage IV
  • Inflammatory breast cancer
  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Inflammatory Breast Neoplasms